TCM
RPRX icon

Teza Capital Management’s Royalty Pharma RPRX Stock Holding History

Teza Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-7,576
Closed -$230K – 736
2024
Q1 		$230K Buy
+7,576
New +$223K 0.03% 488
2023
Q4 		– Sell
-7,995
Closed -$217K – 729
2023
Q3 		$217K Sell
7,995
-152
-2% -$4.51K 0.04% 509
2023
Q2 		$250K Buy
+8,147
New +$276K 0.04% 449
2023
Q1 		– Sell
-20,793
Closed -$822K – 681
2022
Q4 		$822K Buy
+20,793
New +$868K 0.16% 215
2021
Q3 		– Sell
-5,461
Closed -$224K – 556
2021
Q2 		$224K Buy
+5,461
New +$232K 0.04% 504

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Teza Capital Management's RPRX Position: Q2 2024 in Review

Teza Capital Management sold out of Royalty Pharma (RPRX) in Q2 2024, closing a stake of 7,576 shares — an estimated $230K sold.

Teza Capital Management first reported a position in RPRX in Q2 2021 and held it in 5 quarters. The position peaked at $822K in Q4 2022. 378 funds tracked by Wall St. Rank hold RPRX as of Q2 2024.

  • Teza Capital Management reported no remaining Royalty Pharma position as of Q2 2024 after selling out during the quarter.
  • Teza Capital Management sold 7,576 Royalty Pharma shares in Q2 2024, an estimated $230K.
  • Teza Capital Management first reported a position in Royalty Pharma in Q2 2021 and held it in 5 quarters.
  • Teza Capital Management's Royalty Pharma position peaked at $822K in Q4 2022.
  • 378 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2024.

Based on Teza Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.